Evidence map›Paper›PMID 37108391›Full record

ArticleInternational journal of molecular sciences2023

Nanomechanical Characterization of Ovarian Cancer Cell Lines as a Marker of Response to 2c Treatment.

Domenico Tierno, Eros Azzalini, Rossella Farra, Sara Drioli, Fulvia Felluga, Marco Lazzarino, Gabriele Grassi, Barbara Dapas, Serena Bonin

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Special Issue "Resistance to Therapy in Ovarian Cancers".International journal of molecular sciences · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Domenico TiernoDepartment of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.
Eros AzzaliniDepartment of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.ORCID 0000-0002-5193-268X
Rossella FarraDepartment of Life Sciences (DSV), University of Trieste, 34128 Trieste, Italy.
Sara DrioliDepartment of Chemical and Pharmaceutical Sciences (DSCF), University of Trieste, 34127 Trieste, Italy.
Fulvia FellugaDepartment of Chemical and Pharmaceutical Sciences (DSCF), University of Trieste, 34127 Trieste, Italy.ORCID 0000-0001-8271-408X
Marco LazzarinoConsiglio Nazionale delle Ricerche, Istituto Officina dei Materiali (IOM), 34149 Trieste, Italy.ORCID 0000-0003-1077-6569
Gabriele GrassiDepartment of Life Sciences (DSV), University of Trieste, 34128 Trieste, Italy.ORCID 0000-0001-9704-6651
Barbara DapasDepartment of Life Sciences (DSV), University of Trieste, 34128 Trieste, Italy.
Serena BoninDepartment of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.ORCID 0000-0002-7349-0296

Funding

European Commission 667403POR FESR 2014-2020 FRIULI VENEZIA GIULIA ATeNA" 2017, grant J96G17000120005
6 · The paper itself

Abstract

Epithelial ovarian cancers (EOCs) are a heterogeneous group of tumors with different molecular and clinical features. In past decades, few improvements have been achieved in terms of EOC management and treatment efficacy, such that the 5-year survival rate of patients remained almost unchanged. A better characterization of EOCs' heterogeneity is needed to identify cancer vulnerabilities, stratify patients and adopt proper therapies. The mechanical features of malignant cells are emerging as new biomarkers of cancer invasiveness and drug resistance that can further improve our knowledge of EOC biology and allow the identification of new molecular targets. In this study, we determined the inter and intra-mechanical heterogeneity of eight ovarian cancer cell lines and their association with tumor invasiveness and resistance to an anti-tumoral drug with cytoskeleton depolymerization activity (2c).

Indexed as

Antineoplastic AgentsNeoplasms, Glandular and EpithelialOvarian NeoplasmsBiomarkers, TumorCarcinoma, Ovarian EpithelialCell Line, TumorFemaleHumansAntineoplastic AgentsBiomarkers, Tumor2cAFMheterogeneityinvasivenessovarian cancer cell linesresistancestiffness

Identifiers

PMID37108391
PMCPMC10139025

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.